With only $41 million in cash, Tvardi Therapeutics may need to raise additional funds within a one-year period. Click here to ...
For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), ...
The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis ...
For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), ...
CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...
Tivardi Therapeutics shares plunge after phase 2 trial setbacks for TTI-101 in pulmonary fibrosis. Read more here.
DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline ...
(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Idiopathic Pulmonary Fibrosis pipeline constitutes 80+ key companies continuously working towards ...
The Chosun Ilbo on MSN
Jaksade Approved: First New Pulmonary Fibrosis Drug in a Decade
A new drug to alleviate idiopathic pulmonary fibrosis, a condition where the lungs harden and make breathing difficult, has ...
Vicore Pharma Holding AB, unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has ...
STOCKHOLM, SE / ACCESS Newswire / September 30, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback